Advancing Discoveries in Fibrosis
Our team has unmatched expertise in fibrosis biology and is focused on discovering and developing novel targeted therapies to address life-threatening fibrotic diseases. Our research is regularly published in a variety of forums and presented at medical and scientific conferences.
Papers
IPF
Jump to Posters & PRESENTATIONS
JUMP TO Top
-
Dual αvβ6 and αvβ1 Inhibition Over 12 Weeks Reduces Active Type 1 Collagen Deposition in Individuals with Idiopathic Pulmonary Fibrosis: A Phase 2, Double-Blind, Placebo-controlled Clinical Trial
-
Bexotegrast shows dose-dependent integrin αvβ6 receptor occupancy in lungs of participants with idiopathic pulmonary fibrosis: A Phase 2, open-label clinical trial
-
(Supplement) Bexotegrast in patients with idiopathic pulmonary fibrosis: The INTEGRIS-IPF study
-
Bexotegrast in patients with idiopathic pulmonary fibrosis: The INTEGRIS-IPF study
-
Dual inhibition of αvβ6 and αvβ1 reduces fibrogenesis in lung tissue explants from patients with IPF
-
TGF-β as a driver of fibrosis: physiological roles and therapeutic opportunities
-
Dual antagonists of α5β1/αvβ1 integrin for airway hyperresponsiveness
-
Insights into protein-ligand interactions in integrin complexes: Advances in structure determinations
-
The integrin αvβ6 binds and activates latent TGF beta 1: A mechanism for regulating pulmonary inflammation and fibrosis
-
The αvβ1 integrin plays a critical in vivo role in tissue fibrosis
-
Selective αv integrin depletion identifies a core, targetable molecular pathway that regulates fibrosis across solid organs
-
Epithelial-mesenchymal interactions in fibrosis and repair. Transforming growth factor-β activation by epithelial cells and fibroblasts
-
Evaluation of integrin αvβ6 cystine knot PET tracers to detect cancer and idiopathic pulmonary fibrosis
PSC
-
TGF-β as a driver of fibrosis: physiological roles and therapeutic opportunities
-
The αvβ1 integrin plays a critical in vivo role in tissue fibrosis
-
Selective αv integrin depletion identifies a core, targetable molecular pathway that regulates fibrosis across solid organs
-
Epithelial-mesenchymal interactions in fibrosis and repair. Transforming growth factor-β activation by epithelial cells and fibroblasts
-
Integrin αvβ6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies
Posters & Presentations
IPF
ATS May 2025
-
Characterizing the antifibrotic activity of bexotegrast on distinct fibroblast populations in PCLS from multiple ILD subtypes
-
(Oral Presentation) Characterizing the antifibrotic activity of bexotegrast on distinct fibroblast populations in PCLS from multiple ILD subtypes
-
Plasma proteome analysis reveals shared and unique biomarkers of ILD subtypes
-
Single-cell profiling demonstrates the antifibrotic effects of bexotegrast on pathologic lung cell populations in the Presence and Absence of Background Therapy
ERS September 2023
-
Safety, tolerability and antifibrotic activity of bexotegrast: Phase 2a INTEGRIS-IPF Study (NCT04396756)
-
Circulating ITGB6 levels are elevated in patients with idiopathic pulmonary fibrosis and reduced following lung transplant
-
Dual αvβ6/αvβ1 integrin inhibitor bexotegrast reduces fibrogenesis in pathological cell populations present in the fibrotic human lung
Gordon Research Conference August 2023
ATS June 2023
ATS May 2022
-
Combining dual αVβ6/αVβ1 integrin inhibitor, PLN-74809, with standard-of-care therapies has a synergistic effect on reducing fibrogenic gene expression in fibrotic human lung slices
-
PLN-74809, a dual-selective inhibitor of integrins αvβ6 and αvβ1 shows dose-dependent target engagement in the lungs of patients with idiopathic pulmonary fibrosis (IPF)
-
PLN-74809, an oral, dual-selective αvβ6/αvβ1 inhibitor in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF), sustainably reduces transforming growth factor-beta (TGF-β) activity in the lungs of healthy participants with once-daily dosing
-
PLN-74809, a dual-selective inhibitor of αvβ6 and αvβ1, is well tolerated in over 280 healthy participants
-
Therapeutic biomarker discovery in idiopathic pulmonary fibrosis (IPF) through proteomic analysis of precision-cut lung slice (PCLS) supernatants
-
Pharmacological inhibitors of integrin αvβ6 that differentially modulate protein conformation are similarly effective at inhibiting TGF-β signaling in the fibrotic lung
ATS May 2020
ERS September–October 2019
PSC
AASLD November 2024
-
Bexotegrast, an oral inhibitor of αvβ6 and αvβ1 integrins, was shown to improve markers and symptoms of cholestasis and stabilized markers of liver fibrosis in participants with primary sclerosing cholangitis: Week 24 results from the Phase 2 INTEGRIS-PSC trial
-
Identification of novel inflammatory serum and urinary protein biomarkers for PSC
ERS September 2024
-
(Oral Presentation) Safety and tolerability of bexotegrast in Phase 2 trials of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC)
-
Safety and tolerability of bexotegrast in Phase 2 trials of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC)
EASL June 2024
-
Dual alpha-v/beta-6 and alpha-v/beta-1 integrin inhibitor bexotegrast targets TGF-beta inhibition to specific cell types in human liver explant tissue with biliary fibrosis
-
Oral alpha-v/beta-6 and alpha-v/beta-1 integrin inhibitor bexotegrast in primary sclerosing cholangitis: Updated 12-week interim safety and efficacy analysis of the INTEGRIS-PSC Phase 2a trial
ATS May 2024
-
(Oral Presentation) Update on the safety and tolerability of bexotegrast, a dual-selective inhibitor of integrins αvβ6 and αvβ1, in development for idiopathic pulmonary fibrosis and primary sclerosing cholangitis
-
(E-Poster) Update on the safety and tolerability of bexotegrast, a dual-selective inhibitor of integrins αvβ6 and αvβ1, in development for idiopathic pulmonary fibrosis and primary sclerosing cholangitis
AASLD November 2023
-
Oral αvβ6/αvβ1 integrin inhibition in primary sclerosing cholangitis: 12-week interim safety and efficacy analysis of INTEGRIS-PSC, a Phase 2a trial of bexotegrast
-
Inhibition of integrin αVβ1 attenuates profibrogenic gene expression by myofibroblasts in fibrotic human liver explants
-
Dual αVβ6/αVβ1 integrin inhibitor bexotegrast attenuates profibrogenic gene expression across multiple pathologic cell types in human liver explant tissue with biliary fibrosis
-
Oral αVβ6/αVβ1 integrin inhibition in primary sclerosing cholangitis: 12-week interim safety and efficacy analysis of INTEGRIS-PSC, a phase 2a trial of bexotegrast
Gordon Research Conference August 2023
EASL June 2023
-
INTEGRIS-PSC Phase 2a study: Evaluating the safety, tolerability, and pharmacokinetics of bexotegrast (PLN-74809) in participants with primary sclerosing cholangitis
-
Dual alpha-v/beta-6 and alpha-v/beta-1 integrin inhibitor bexotegrast attenuates profibrogenic gene expression of myofibroblasts in human liver explant tissue with biliary fibrosis
-
Non-invasive imaging method demonstrates anti-fibrotic efficacy of a dual integrin alpha-v/beta-6 and alpha-v/beta-1 inhibitor in a rat model of biliary fibrosis
AASLD November 2019
Oncology
SITC November 2023
-
Phase 1a trial of PLN-101095, an integrin αvβ8 and αvβ1 inhibitor, as monotherapy and in combination with pembrolizumab, in treatment-resistant patients with advanced or metastatic solid tumors
-
Integrin αvβ1 is expressed in multiple solid tumors and drives the adhesion of cancer-associated fibroblasts to latent TGF-β
-
Selective targeting of integrins αVß8 and αVß1 within the dynamic ecosystem of pancreatic cancer to improve overall anti-tumor response